Bone Biologics Corp financial data

Symbol
BBLG, BBLGW on Nasdaq
Location
2 Burlington Woods Drive,, Suite 100,, Burlington, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Former names
AFH ACQUISITION X, INC. (to 9/15/2014)
Latest financial report
Q1 2024 - May 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 25.6 % -35.6%
Return On Equity -152 % -57.8%
Return On Assets -121 % -75.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.1M shares -93.4%
Common Stock, Shares, Outstanding 1.02M shares -93.9%
Entity Public Float 4.16M USD -5.47%
Common Stock, Value, Issued 1.02K USD -93.9%
Weighted Average Number of Shares Outstanding, Basic 661K shares +883%
Weighted Average Number of Shares Outstanding, Diluted 661K shares +883%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 4.56M USD +10.4%
General and Administrative Expense 2.62M USD +31.8%
Operating Income (Loss) -7.18M USD -17.3%
Nonoperating Income (Expense) 37.6K USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -2.52M USD -33.6%
Income Tax Expense (Benefit) 33.1K USD
Net Income (Loss) Attributable to Parent -6.1M USD -35.5%
Earnings Per Share, Basic 19.9 USD/shares +97.6%
Earnings Per Share, Diluted 19.9 USD/shares +97.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.19M USD +6.43%
Assets, Current 3.84M USD
Assets 3.84M USD -43.4%
Liabilities, Current 165K USD -95.9%
Liabilities 165K USD -95.9%
Retained Earnings (Accumulated Deficit) -81.8M USD -8.07%
Stockholders' Equity Attributable to Parent 3.67M USD +32.6%
Liabilities and Equity 3.84M USD -43.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.3M USD +3.45%
Net Cash Provided by (Used in) Financing Activities 1.5M USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 1.02M shares -93.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 201K USD
Deferred Tax Assets, Valuation Allowance 20.4M USD +0.29%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 20.4M USD +0.29%
Deferred Tax Assets, Operating Loss Carryforwards 9.59M USD -12.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 20M shares 0%
Additional Paid in Capital 85.4M USD +8.96%
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%